ReShape Lifesciences Faces Nasdaq Delisting
Ticker: HIND · Form: 8-K · Filed: Dec 2, 2024 · CIK: 1427570
| Field | Detail |
|---|---|
| Company | Reshape Lifesciences Inc. (HIND) |
| Form Type | 8-K |
| Filed Date | Dec 2, 2024 |
| Risk Level | high |
| Pages | 2 |
| Reading Time | 2 min |
| Key Dollar Amounts | $0.001, $2.5 million, $1,487,000 |
| Sentiment | bearish |
Sentiment: bearish
Topics: delisting, nasdaq, compliance
Related Tickers: RSLS
TL;DR
Nasdaq wants to kick ReShape off the exchange, they have a month to fix it or bye-bye stock.
AI Summary
ReShape Lifesciences Inc. received a notice on November 25, 2024, indicating it failed to meet the continued listing standards of The Nasdaq Stock Market LLC. The company has until December 26, 2024, to submit a plan to regain compliance. Failure to do so could result in the delisting of its common stock.
Why It Matters
This filing signals potential delisting from Nasdaq, which could significantly impact the liquidity and trading of ReShape Lifesciences' stock.
Risk Assessment
Risk Level: high — Failure to regain compliance with Nasdaq listing standards could lead to delisting, severely impacting the company's stock value and liquidity.
Key Numbers
- 1 month — Compliance Period (Timeframe to regain Nasdaq listing standards.)
Key Players & Entities
- ReShape Lifesciences Inc. (company) — Registrant
- The Nasdaq Stock Market LLC (company) — Listing Exchange
- November 25, 2024 (date) — Date of Notice
- December 26, 2024 (date) — Compliance Deadline
FAQ
What specific listing standard did ReShape Lifesciences fail to meet?
The filing states that the company received a notice of failure to satisfy a continued listing rule or standard, but does not specify which particular rule was violated.
What is the deadline for ReShape Lifesciences to submit a compliance plan?
The company has until December 26, 2024, to submit a plan to regain compliance with Nasdaq's listing standards.
What is the consequence of failing to regain compliance?
If ReShape Lifesciences fails to regain compliance, its common stock may be delisted from The Nasdaq Stock Market.
Has ReShape Lifesciences previously faced delisting concerns?
The filing does not provide historical information on previous delisting concerns.
What is the company's principal executive office address?
The company's principal executive offices are located at 18 Technology Drive, Suite 110, Irvine, CA 92618.
Filing Stats: 516 words · 2 min read · ~2 pages · Grade level 11.7 · Accepted 2024-12-02 16:05:20
Key Financial Figures
- $0.001 — nge on which Registered Common stock, $0.001 par value per share RSLS The Nasdaq C
- $2.5 million — Capital Market to maintain a minimum of $2.5 million in stockholders' equity for continued l
- $1,487,000 — the Company's stockholders' equity was $1,487,000. Under the Nasdaq Listing Rules the Com
Filing Documents
- tm2419158d7_8k.htm (8-K) — 25KB
- 0001104659-24-124568.txt ( ) — 193KB
- rsls-20241125.xsd (EX-101.SCH) — 3KB
- rsls-20241125_lab.xml (EX-101.LAB) — 33KB
- rsls-20241125_pre.xml (EX-101.PRE) — 22KB
- tm2419158d7_8k_htm.xml (XML) — 3KB
01Notice
Item 3.01Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard; Transfer of Listing. On November 25, 2024, ReShape Lifesciences Inc. (the "Company") received a written notice (the "Notice") from the Listing Qualifications department (the "Nasdaq Staff") of the Nasdaq Stock Market ("Nasdaq") indicating that the Company is not in compliance with Nasdaq Listing Rule 5550(b)(1), which requires companies listed on the Nasdaq Capital Market to maintain a minimum of $2.5 million in stockholders' equity for continued listing. As of September 30, 2024, the Company's stockholders' equity was $1,487,000. Under the Nasdaq Listing Rules the Company has 45 calendar days to submit a plan to regain compliance. If the Company's plan is accepted, the Nasdaq Staff can grant an extension of up to 180 calendar days from the date of the Notice to evidence compliance.The Company intends to actively monitor its performance with respect to the listing standards and will consider available options to resolve the deficiency and regain compliance with the Nasdaq rules.
SIGNATURES
SIGNATURES Pursuant to the requirements of the Securities Exchange Act of 1934, as amended, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized. RESHAPE LIFESCIENCES INC. By: /s/ Paul F. Hickey Paul F. Hickey Chief Executive Officer Dated: December 2, 2024